{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-25-000066","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.477001+00:00","generated_at":"2026-05-20T03:00:58.641551+00:00","sec_items":["7.01","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Arcus reports 46% confirmed ORR for casdatifan + cabozantinib in ccRCC post-immunotherapy","bullets":["Phase 1/1b ARC-20 interim analysis shows 46% cORR (11/24) per RECIST v1.1; median follow-up 5.3 months.","Response includes 1 complete response (4%) and 10 partial responses (42%); 50% had stable disease.","Safety evaluable population (n=42) showed acceptable safety profile with no new unexpected risks or overlapping toxicity.","Study evaluates casdatifan 100mg QD plus cabozantinib 60mg QD in patients with ccRCC who progressed on prior immunotherapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-25-000066","json":"https://secwatch.observer/filing/0001724521-25-000066.json","markdown":"https://secwatch.observer/filing/0001724521-25-000066.md","text":"https://secwatch.observer/filing/0001724521-25-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000066/0001724521-25-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452125000066/rcus-20250601.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T03:00:58.641551+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}